|
Aug 27
|
Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting
|
|
Jun 20
|
MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders
|
|
Jun 20
|
Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
|
|
May 17
|
Erasca restructures; Novartis moves to complete MorphoSys deal
|
|
Jan 30
|
MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability
|
|
Dec 11
|
MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study
|
|
Jun 26
|
Wells Fargo Predicts up to 125% Rally for These 2 Stocks — Here’s Why They Have Solid Upside
|
|
Apr 27
|
Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023
|